Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

222
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
222
Crossover Experiments01:16

Crossover Experiments

4.5K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
4.5K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

527
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
527
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

752
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
752

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

Leukemia·2026
Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026
Same author

Remission with residuals, but no cure.

Blood advances·2026
Same author

Chronic Lymphocytic Leukemia Through the Spectrum: Frontline Therapy, Sequencing With Subsequent Therapy, and Treatment of Double-Refractory Patients.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.

BMC health services research·2026
Same author

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.

Haematologica·2026

Related Experiment Video

Updated: Jan 9, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Othman Al-Sawaf1, Janina Stumpf1, Can Zhang1

  • 1Department I of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany.

The New England Journal of Medicine
|December 8, 2025
PubMed
Summary
This summary is machine-generated.

Fixed-duration venetoclax regimens were noninferior to continuous ibrutinib for chronic lymphocytic leukemia (CLL) progression-free survival. This study compared venetoclax-obinutuzumab and venetoclax-ibrutinib against ibrutinib in previously untreated CLL patients.

More Related Videos

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.1K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

537

Related Experiment Videos

Last Updated: Jan 9, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.1K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

537

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Current chronic lymphocytic leukemia (CLL) treatment involves continuous Bruton's tyrosine kinase inhibitors (BTKIs) or fixed-duration venetoclax-based regimens.
  • Direct comparisons between these two main therapeutic strategies are lacking.

Purpose of the Study:

  • To compare the efficacy and safety of fixed-duration venetoclax-obinutuzumab and venetoclax-ibrutinib versus continuous ibrutinib in previously untreated CLL patients.
  • To evaluate progression-free survival (PFS) as the primary endpoint and minimal residual disease (MRD) and overall survival (OS) as secondary endpoints.

Main Methods:

  • Phase 3, randomized, investigator-initiated trial involving 909 patients with previously untreated CLL.
  • Patients were assigned to fixed-duration venetoclax-obinutuzumab, fixed-duration venetoclax-ibrutinib, or continuous ibrutinib.
  • Primary endpoint: investigator-assessed PFS; Secondary endpoints: MRD, response, OS, safety.

Main Results:

  • Three-year PFS was noninferior for venetoclax-obinutuzumab (81.1%) and venetoclax-ibrutinib (79.4%) compared to ibrutinib (81.0%).
  • Undetectable MRD post-treatment was significantly higher in the venetoclax-obinutuzumab group (73.3%) compared to venetoclax-ibrutinib (47.2%) and ibrutinib (0%).
  • Three-year OS was high across all arms: 91.5% (venetoclax-obinutuzumab), 96.0% (venetoclax-ibrutinib), and 95.7% (ibrutinib).

Conclusions:

  • Fixed-duration venetoclax-based treatments demonstrate noninferior PFS compared to continuous ibrutinib in previously untreated CLL.
  • These findings support fixed-duration venetoclax regimens as effective alternatives to continuous BTKI therapy in CLL.
  • Higher rates of MRD negativity were observed with venetoclax-containing regimens, suggesting potential for deeper responses.